Immune cell therapy takes on HPV
NCT ID NCT03351855
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This trial tests whether infusing HPV-specific immune cells (HPV-CTLs) can safely reduce or clear HPV infection in people who haven't responded to standard treatments. Up to 100 participants will receive 2 to 4 infusions of these cells. The study measures safety and viral load changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV-specific immune cells (HPV-CTLs)
What this could lead to
If successful, this could offer a new treatment option for persistent HPV infections that don't respond to standard therapies.
What could go wrong
This is an early phase 1/2 trial with only 100 participants, so results may not apply broadly. Risks include immune reactions or lack of viral clearance.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.